



University of Missouri

Scott Endowed Program in Veterinary Oncology

- Home
- About Us
- Your Visit
- About Cancer
- Clinical Trials
- Publications & Research
- Cancer Therapies
- Cancer Effects
- How You Can Help
- Links

Dogs with Cancer Needed for Clinical Trials

The Oncology Service at the University of Missouri College of Veterinary Medicine is seeking dogs with cancer to participate in clinical trials evaluating novel treatments. Clinical trials typically offset some or all of the cost of treatment while on trial and help advance our knowledge in the fight against cancer. We are seeking dogs with the following cancers:

- Newly diagnosed B cell lymphoma to participate in a chemotherapy trial of doxorubicin chemotherapy with an herb or placebo. The trial tests whether the herb, artemisinin, will improve response to standard chemotherapy for canine lymphoma and serves as a model for treatment of breast cancer in women.
 - Soft-tissue sarcomas, cutaneous carcinomas, and melanomas to participate in one of two fully funded trials. The first is an immunotherapy trial. Dogs will be carefully evaluated with CT and PET scans, receive an infusion of a new immunotherapy agent, and monitored by blood collection and follow-up CT and PET scans. The second trial involves a novel chemotherapy agent in conjunction with standard chemotherapy. Dogs participating in this chemotherapy trial will receive further financial support for therapy following the trial.
-
- **Prostate cancer** to receive radioactive gold nanoparticles as a treatment for the primary prostate tumor. Only dogs and men frequently develop prostate cancer. This trial is testing a new, non-surgical approach to controlling the primary prostate tumor.
 - **Any tumor** except osteosarcoma, lymphoma, or prostate cancer to receive a novel nanoparticle paclitaxel chemotherapy. This study is evaluating the potential toxicity and efficacy of a nanoparticle preparation of the potent chemotherapy drug paclitaxel.
 - **Mast cell tumors** to test a new combination of existing chemotherapy drugs. Dogs in this trial receive Palladia and lomustine to shrink the mast cell tumors as primary management or in preparation for surgery.
 - **Relapsed lymphoma.** Lymphoma is most deadly when chemotherapy has stopped working. This trial is evaluating a new approach to sensitizing resistant lymphoma cells to standard lomustine chemotherapy.

Enrollment in clinical trials requires meeting specific criteria for each trial. Please contact the Oncology Service at 573-882-7821 for more information on getting help for your dog through a clinical trial.